Aadi Bioscience (NASDAQ:AADI) Trading 1.1% Higher - Here's What Happened

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) shares were up 1.1% during trading on Thursday . The stock traded as high as $1.92 and last traded at $1.88. Approximately 25,278 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 253,080 shares. The stock had previously closed at $1.86.

Aadi Bioscience Trading Up 1.1%

The stock's 50 day moving average is $1.79 and its two-hundred day moving average is $2.23. The stock has a market capitalization of $46.43 million, a price-to-earnings ratio of -0.82 and a beta of 0.68.

Institutional Trading of Aadi Bioscience

Several hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP grew its holdings in Aadi Bioscience by 95.2% in the 4th quarter. Two Sigma Advisers LP now owns 61,686 shares of the company's stock valued at $195,000 after buying an additional 30,086 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Aadi Bioscience by 305.2% in the fourth quarter. Two Sigma Investments LP now owns 68,555 shares of the company's stock valued at $216,000 after acquiring an additional 51,638 shares during the period. Northern Trust Corp grew its stake in shares of Aadi Bioscience by 33.1% in the fourth quarter. Northern Trust Corp now owns 91,151 shares of the company's stock valued at $288,000 after acquiring an additional 22,677 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Aadi Bioscience by 23.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock valued at $364,000 after acquiring an additional 22,100 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Aadi Bioscience by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company's stock worth $686,000 after acquiring an additional 8,546 shares during the period. 52.08% of the stock is owned by institutional investors and hedge funds.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.